source
- Disc spins past FDA rejection with ‘overwhelmingly positive’ phase 3 data for rare disease drugA phase 3 trial of Disc Medicine’s bitopertin has hit both co-primary endpoints and all secondary endpoints, positioning the biotech to refile for approval of the once-rejected rare disease drug ca…
- Eli Lilly teams with Hong Kong's Metis TechBio in up to $1.1 billion AI nanoparticle partnershipEli Lilly has entered a partnership with Hong Kong‑based Metis TechBio to access an artificial‑intelligence driven platform for designing lipid nanoparticles that can improve drug delivery. The co…